Blood Cancers

Blood Cancers

• Locations
• Treatments & Services
• Patient Forms
• Newly Diagnosed
• Maryland Oncology Hematology and The US Oncology Network Welcome Cynthia Plate M.D. F.A.C.S, Specialist In Breast Surgery
• Protecting our patients against Coronavirus
• What is a Cancer Clinical Trial?
• Facts You Need to Know About Colorectal Cancer
• COVID-19 Vaccines for Patients Frequently Asked Questions* (FAQ)
• 6 Surprising Signs and Symptoms of Breast Cancer
• The Rise of Colorectal Cancer in Young Adults
• Maryland Oncology Hematology Welcomes Colette Magnant, MD, FACS to Their Expanding Breast Surgical Oncology Team
• COVID-19 Vaccine and Cancer: What you need to know
• Maryland Oncology Hematology Gives New Meaning to Personalized Cancer Care
• Maryland Oncology Hematology Commercial: Expert Care, Close to Home
• Mohit Narang M.D. was a Guest on Great Day Washington
• Health Insurance Update
• Kashif Firozvi, M.D. was a guest on Great Day Washington
• Talking Cancer Prevention on Great Day Washington
• Privacy Policy
• Laboratory
• Medically Integrated Dispensary
• Financial Counseling
• For Patients
• Patient Portal
• What to Expect
• Bill Pay
• Second Opinions
• Emergencies & Phone Calls
• About Us
• The Paxman Scalp Cooling System
• Patient Resources
• Radiation Oncology
• Covid 19
• Patient Services
• Blogs
• Genomic Testing
• Home
• Shannon O’Connor, MD
• Courtney Ackerman, MD
• Kashif Ali, MD
• Nouman Asif, MD
• Nicholas DeMonaco, MD
• Alida Espinoza, MD
• Nicholas J Farrell, MD
• Kashif Firozvi, MD
• Ari D Fishman, MD
• Rita Gupta, MD
• Carolyn Hendricks, MD
• Vinni Juneja, MD
• Edward J Lee, MD
• Syed Shahid Mahmood, MD
• Jose Mendoza, MD
• Andrew Mener, MD
• Frederick Min, MD
• Mohit Narang, MD
• Vivek Patil, MD
• Tejaswi R Sastry, MD
• George Sotos, MD
• Jun Sun, MD
• Sadaf Taimur, MD
• Deepnarayan Tiwarri, MD
• John Wallmark, MD
• Surupa Sen Gupta, MD
• Cynthia Plate, MD
• Margaret DeRosa, CRNP
• Kimberly Grossnickle, CRNP
• Laura Hostovich, AOCNP
• Elizabeth Rauschenberg, CRNP
• Tracey Royer, DNP
• Adam Schmuckler, PA-C
• Amy Tissiere, LCSW-C
• Jason Taksey, MD
• Ravin Garg, MD
• Stuart Selonick, MD
• Jeanine L Werner, MD
• David Weng, MD PhD
• Benjamin Bridges, MD
• Carol Tweed, MD
• Adam Goldrich, MD
• Jacqueline Shanahan BSN
• Debbie Dey, LCSW-C
• Harminder S. Sethi, MD
• Shruti Murali, MD
• New Patient
• Current Patient
• Our Team
• Medical Professionals
• Blood Disorders
• Prescription Fills
• Targeted Therapy
• Chemotherapy
• Surgical Services
• Hematology
• Clinical Trials
• Breast Surgeon
• Colon and Rectal Surgeon
• Gynecologic Oncology
• Physicians
• Advanced Practice Providers (APP)
• Nurse Navigation
• Social Workers
• Genetics
• Dietitian
• Checklist for Medical Records
• Insurance Benefits & Financial Resources
• Mission Statement
• News / Newsletter
• About US Oncology
• Weapons Policy
• Site Map
• Isabel Rose, PA-C
• Najeff Waseem, MD
• Clinical Trial FAQs
• Laryngeal
• Lip and Oral
• Nasopharyngeal
• Paranasal Sinus and Nasal Cavity
• Salivary Gland
• Understanding Your Cancer Care Team
• Ovarian
• Prostate
• Radiation Technologies
• Radiation Therapy for Head and Neck Cancer
• Radiation Treatments for Lung Cancer
• Skin Soft Tissue Sarcoma
• Squamous Cell Head and Neck
• Precision Medicine
• Thyroid
• Side Effect Management – Anemia
• Side Effect Management – Chemo Brain
• Side Effect Management – Diet and Exercise
• Side Effect Management – Emotional Wellbeing
• Side Effect Management – Fatigue
• Side Effect Management – Dealing with Hair Loss
• Side Effect Management: Nausea and Vomiting
• Side Effect Management: Pain from Treatments
• Side Effect Management – Sexual Complications
• Side Effect Management – Skin and Nail Care
• Survivorship for Your Brain and Body
• Survivorship
• Survivorship: You’re Not Alone
• Survivorship: The Return to Work After a Cancer Diagnosis
• Albert J. Steren, MD
• Leslie Lawson, CRNP
• Maria Mikulski, CRNP
• Sarah Regan, MD
• Tomeeka Hawthorne, MSN
• Danubia Hester, MD
• Cancers
• Blood Cancers
• Blood Disorders
• Anemia
• Essential Thrombocythemia
• Search Results
• Lung
• Surviorship – New Normal
• Phases
• What Our Social Workers Do
• Find a Trial
• Ali Bukhari, MD
• Jaynah Mistry, PA-C
• Alessandra Fitzpatrick, PA-C
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors MK 3475-158/KEYNOTE-158
• USOR 17079: Flex Registry Evaluate New Gene Express
• USOR 21320: Ph1/2 REQORSA Osim EDFR NSCLC Acclaim-1
• USOR 21462: Adjuvant trial for HER2+ BC Ph3 HER2/neu BC FLAMINGO-01
• USOR 22244: Ph3 Iberdomide Maintenance Following Autologous Stem Cell Transplant in newly dx MM
• Lin Chen, MSN
• Shreya Sinha, MD
• Tori Eskay, PA-C
• Neha Bhooshan, MD PhD
• USOR 21541: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50%
• Contact Us
• Denise R. Gooch, MD
• Doxie.me For Columbia
• Telehealth
• Chemotherapy Education
• Chemotherapy Introduction Video
• Nadine Thompson, PA-C
• Sara Bogeum Kim, RN
• An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)
• Nutrition and Cancer: Harnessing the Healing Power of Food for Cancer Patients
• USOR 21271: Ph2 ZN-c3 Uterine Carcinoma (ZN-c3-004 | GOG 3065)
• Navigating the Challenges: Practical Tips for Managing Cancer Treatment Symptoms
• USOR 22326: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
• The Power of Support: Building a Strong Cancer Survivor Network
• Kimberly Brice, DNP
• Understanding Your Diagnosis: Cervical Cancer [SERIES]
• USOR 21270: Trial for cyclin E1-positive PROC Ph2 ZN-c3 Tumor DNA Repair CCGA (ZN-c3-005/GOG 3066) *STAR*
• Cancer Recurrence: Understanding and Coping with the Risk
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis XPORT-MF-034 (SENTRY)
• MOH Research Video
• The Role of Genetic Mutations in Cancer Development
• Understanding Your Diagnosis: Gallbladder and Bile Duct Cancer [SERIES]
• Cancer Causes and Risk: What You Need to Know
• Radiation Therapy for Breast Cancer
• Outage Information
• Appointment Request Submitted
• Non-Oncological Infusion
• Study of Acalabrutinib and Rituximab in Untreated Elderly and/​or Frail Patients With DLBCL (ACRUE)
• USOR 23189: Trial for HR+/HER2-low mBC Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)
• Keisha Hinds, CRNP
• Breast
• A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia XPORT-MF-044 (SENTRY-2)
• Colorectal
• USOR 22322: 1L KRASG12C NSCLC Ph3 LY3537982 + Pembro vs. Placebo + Pembro 1L KRAS G12C NSCLC
• USOR 22067: Advanced Solid Tumors incl Lung, Ovarian Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors
• USOR 23059: 1L Trial for ER+/HER2- MBC Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast
• Jody Beck, MSN
• Black Women and Breast Cancer
• USOR 23292: Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors_ART0380C001 *STAR*
• Change Healthcare Notice
• Dong (Jake) Kim, MD
• Andrew Li, MD
• Jasmine Ebott, MD
• USOR 20266: 1L/2L mCRC Ph1a/1b TTX-080 +/-Pembro or Cetux in Select ST (TTX-080-001)
• Caroline Wiseman, MSN
• USOR 23235: 1L NSCLC Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC
• Educational Videos
• Marissa Davidson, DNP
• USOR 23234: Unresected LA HNSCC Ph3 Study of Volrustomig (MEDI5752) Advanced-HNSCC LA-HNSCC (eVOLVE-HNSCC)
• USOR 23133: Trial for HR+/HER2- MBC Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292)
• Receiving an Abnormal Mammogram Report, What Next?
• USOR 22333: Trial for 2L+ HER2+ MBC Ph2 Tucatinib combo w/ Doxil for HER2+ mBC (BRE 381)
• USOR 23266: Adjuvant trial for ER+/HER2- BC Ph3 study with HR+ HER2 negative breast cancer who have completed (OVELIA Study)
• Advancements in Lung Cancer Treatment Provide Hope for Maryland Oncology Hematology Patients
• USOR 23031: Relapsed/Refractory Multiple Myeloma Ph2 TECVAYLI in multiple myeloma patients (IIT MM165)
• Donation Confirmation
• Donation Failed
• Donor Dashboard
• MOH Cares Donation
• MOH Cares Foundation
• Finding Tranquility and Well-being During the Holidays while Coping with Cancer
• USOR 23236: Unresected LA HNSCC Ph3 Study to dostarlimab in patients with advanced HNSCC
• USOR 22320: Ph3 Durvalumab & PDL1+ Dato-DXd vs Pembrolizumab BC (TROPION-Breast05)
• USOR 24075: Trial for HER2+ MBC Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer
• Ari Elman, MD
• Lindsey Wise LCSW-C
• Self-Collection for HPV Testing Provides More Accessibility for Cervical Cancer Screening
• Office Closures
• USOR 21181: mCRPC Ph2b ZEN003694 Enza PC
• USOR 23328: Ph2 study of BI 1810631 for the treatment of HER-2 mutated solid tumors *STAR*
• USOR 24004: 2-3L R/M HNSCC Ph3 study to evaluate to treat patients with HNSCC *STAR*
• Nadia Ashai, MD
• USOR 22026: Ph3 Extension Trial Pembro Adv Tumors
• USOR 23335: 1L Cutaneous Melanoma Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma
• Randolph Surgical
• USOR 24112: Trial for CLDN6-expressing plt-resistant ovarian cancer (TORL123-002)
• Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery: Precision Treatment for Cancer
• USOR 24151: Adjuvant trial for ER+/HER2-BC Ph3 study of standard endocrine therapy with breast cancer
• Advanced Care Planning
• Mobile Home
• Navigating Cancer Care with the Help of Independent Cancer Centers
• Eileen Byrne, CRNP
• Cancer Genetic Risk Assessment
• **TEST** MOH Cares Donation
• Ariuka Arya, MSN, FNP-C
• USOR 24189: 1L EGFRm LA or mNSCLC Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS)
• USOR 24100: Trial for adv/rec endometrial cancer w/PI3K/AKT/mTOR mutation Ph2 clinical trial with paclitaxel in patients with endometrial cancer (FTH-PIK-201)
• USOR 23329: MYLUNG/ 23329/ LUN 576
• Chemotherapy Education Introduction Video- Spanish
• Maryland Oncology Hematology Attends Bill Signing Ceremony at Maryland Capitol
• Reduce the Risk of Cancer at Your Summer BBQ
• Hormone Replacement Therapy and Breast Cancer: What You Need to Know
• Susan Prestera, MSN
• Jasmine Burge, MSN
• Samir Kanani, MD
• Sean Cronin, MD
• USOR 24310: 2L mHRPC/mCRPC Ph1/1b single agent in combo with an androgen receptor in patients with prostate
• USOR 24301: Neoadjuvant HER2+ BC Accelero Ph2 randomized open label study of neoadjuvant zanidatamab + chemo in HER2+ breast
• USOR 23251: 1L HR+/HER2- MBC with BRCA1/2 or PALB2 mutations Ph3 AZD5305 with HR+ HER2 negative advanced breast cancer (EvoPAR-Breast01)
• Jessica Adams, MSN, AGPCNP
• Accessibility Policy
• Paul Bannen, MD
• Frederick Smith, MD
• Colorectal Cancer is Increasing in Young Adults: What You Need to Know
• Regina Hampton, MD
• How Do I Manage Fatigue During Cancer Treatment?
• Advancing Precision Medicine with Bispecific Antibody Therapy at Maryland Oncology Hematology
• White Blood Cell Disorders
• Thank You for Submitting your Referral
• Thank You for your Appointment Request
• Yaquelin Guzman, PA-C
• Michaela Verna, MS, CGC
• USOR 22332: Ph3b Adjuvant Ribociclib HR+HER2 Breast Cancer (Adjuvant Wider)
• USOR 24246: Ph2 Study of Fruquintinib plus FOLFIRI as 2L Treatment for mCRC
• NALIRIFOX Expands Frontline Options in Metastatic Pancreatic Cancer Ft. Dong Kim, MD
• USOR 24152: 1L HER2+ G/GEJ Ph3 study of ARTEMIDE-GASTRIC01 in combo with pembro FIL gastric cancer (ARTEMIDE-Gastric01)
• USOR 21498: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC *STAR*
• USOR 24041: Resectable stage II-IIIB NSCLC PH3 Study of WWO V940 in NSCLC for patients with doublet chemo followed by surgery
• Mark G. Goldstein, MD
• USOR 24257: 2L Urothelial Cancer Ph3 study of (Dato-Dxd) in subjects with met. Urothelial Carcinoma TU03
• Jennifer Vaz, MD
• PALbociclib CoLlaborative Adjuvant Study (PALLAS)
• A Study for CTC Expression and cfDNA/​RNA Assessment in Metastatic Breast Cancer Patients (CTC-EXPRESS)
• An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies MS100070_0176
• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations F8394-201
• Ahmad R Cheema, MD
• USOR 25091: 2L+ PD-L1 ≥1% NSCLC Ph3 Study to evaluate PF-08046054 vs Docetaxel in PD-L1+ NSCLC
• USOR 25154: 1L mCRC Ph2/3 BMS-986545 + Chemotherapy vs Bevacizumab in Met CRC
• USOR 25156: 1L mNSCLC Ph3 PF-08634404 + Chemo vs Pembro + Chemo in Locally Advanced or Metastatic NSCLC
• Study on HR+ and HER2-Low (IHC 1+ or 2+ with ISH negative) and HER2-Ultralow (IHC0 with membrane staining) MBC (ENHERTU)
• Can the HPV Vaccine Reduce the Danger of Cervical Cancer?
• Cervical Cancer Treatment: What You Need to Know
• Rylie Chambers, MSN